Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04883905 · ClinicalTrials.gov registry record
ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)
A clinical trial of Acute Hepatic Porphyria, sponsored by Alnylam Pharmaceuticals.
- Recruiting
- Registry status
- 150
- Enrollment target
- 20
- Study locations
NCT04883905: Recruiting study of Acute Hepatic Porphyria, sponsored by Alnylam Pharmaceuticals.
NCT04883905 is a study of Acute Hepatic Porphyria that is actively recruiting participants, run by Alnylam Pharmaceuticals. The registered enrollment target is 150 participants. The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04883905, a study of Acute Hepatic Porphyria, is actively recruiting participants, sponsored by Alnylam Pharmaceuticals.
- RECRUITING
- Registry status
- 150 participants
- Enrollment target
- 20
- Study locations
Study Summary
This global patient registry is being conducted to characterize the natural history and real-world clinical management of patients with AHP, and to further characterize the real-world safety and effectiveness of givosiran and other approved AHP therapies.
Primary Outcome
Selected events of interest are defined as hepatic events (including hepatic neoplasia), renal events, thromboembolic events, and pancreatitis.
Conditions Studied
Study Locations (20)
Other
- Clinical Trial Site - Brussels
- Clinical Trial Site - Leuven
- Clinical Trial Site - Bordeaux
- Clinical Trial Site - Paris
- Clinical Trial Site - Toulouse
- Clinical Trial Site - Berlin
- Clinical Trial Site - Chemnitz
Alabama
- Clinical Trial Site - Birmingham
Arizona
- Clinical Trial Site - Gilbert
California
- Clinical Trial Site - San Francisco
Maryland
- Clinical Trial Site - Baltimore
Massachusetts
- Clinical Trial Site - Boston
Minnesota
- Clinical Trial Site - Minneapolis
New York
- Clinical Trial Site - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2021-04-26 |
| Est. Completion | 2027-04-01 |
What NCT04883905 shows while recruiting
NCT04883905 is an observational study that tracks outcomes without assigning an intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Acute Hepatic Porphyria appearing as the primary indexed condition, and to 0 interventions.
NCT04883905 names 20 study sites across 14 states, led by Other, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT04883905 about?
NCT04883905 is a clinical study titled "ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)". This global patient registry is being conducted to characterize the natural history and real-world clinical management of patients with AHP, and to further characterize the real-world safety and effectiveness of givosiran and other approved AHP therapies.
What is the current status of trial NCT04883905?
This trial is currently recruiting. The enrollment target is 150 participants. The study started on 2021-04-26. Estimated completion is 2027-04-01.
What conditions does trial NCT04883905 study?
This clinical trial studies the following conditions: Acute Hepatic Porphyria.
Who is sponsoring clinical trial NCT04883905?
This trial is sponsored by Alnylam Pharmaceuticals, which has 49 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04883905 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Hepatic Porphyria
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI